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not always correctly take erlotinib without food. Associated 
risk factors were older age, suboptimal adherence, ocular 
symptoms and stomatitis (all p < 0.05). After 1 month of 
treatment, fatigue (91 %) and rash (86 %) were the most 
common symptoms reported. AUCss of erlotinib was higher 
in patients with rash and patients with moderate–severe 
anorexia (both p < 0.05).
Conclusion Though adherence to erlotinib treatment is 
generally high, non-adherence might be an issue in a con-
siderable number of patients. To support optimal erlotinib 
intake, clinicians need to take adequate measures to ame-
liorate symptoms and to address adherence and correct 
intake without food. Especially older patients and those 
who experience stomatitis may need extra attention.
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Abstract 
Purpose Erlotinib is an orally administered tyrosine 
kinase inhibitor used for treatment of non-small cell lung 
cancer. Understanding actual use of medication is essential 
for optimizing treatment conditions.
Methods In this multicentre prospective observational 
study, patients starting erlotinib treatment were followed 
for 4 months. Adherence was assessed using a medication 
event monitoring system (MEMS). Area under the curve 
(AUC) was determined after 1, 2 and 4 months. Before start 
and at monthly intervals, patients filled out questionnaires 
about attitude towards medication and disease, quality of 
life, symptoms and use in daily practice.
Results Sixty-two patients (median age 63.5 years, 53 % 
male) were included of whom 15 were still on treatment 
after 4 months. MEMS data of 55 patients revealed a mean 
adherence of 96.8 ± 4.0 %. Over one-third of patients had 
an adherence rate <95 %. At 1 month, 21 % of patients did 
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Introduction
Erlotinib is an orally administered tyrosine kinase inhibi-
tor (TKI) of the epidermal growth factor receptor (EGFR) 
indicated as first-line treatment for advanced non-small 
cell lung cancer (NSCLC) in patients with activating 
EGFR mutations and as second- and third-line treatment 
in patients with EGFR wild-type NSCLC. In the pivotal 
study, erlotinib prolonged survival, reduced tumour-
related adverse events and improved quality of life (Shep-
herd et al. 2005; Bezjak et al. 2006). Response to erlotinib 
is highly dependent on the mutation status of EGFR in 
tumour tissue (Cadranel et al. 2012; Petrelli et al. 2012a). 
The prognosis is particularly poor in patients with EGFR 
wild-type, while substantially better in patients with 
EGFR mutations treated first line with erlotinib (Petrelli 
et al. 2012a). The most common adverse events of erlo-
tinib occurring in >10 % of patients are skin rash, ano-
rexia, diarrhoea, (kerato) conjunctivitis and fatigue (EMA 
2014; Shepherd et al. 2005). In another meta-analysis of 
24 trials in which the EGFR mutation status was not taken 
into account, skin rash was found to be an independent 
predictive factor for survival and progression (Petrelli 
et al. 2012b). In addition, patients who developed grade 
2–4 rash had a higher chance to respond to treatment as 
compared to patients without rash (Petrelli et al. 2012b). 
Dose increase to achieve rash in individual patients, how-
ever, has resulted in controversial findings (Mita et al. 
2011; Brahmer et al. 2014). From a patient’s view, drug-
induced symptoms may induce considerable physical 
and psycho-social discomfort, which in daily practice are 
known to affect medication adherence (Verbrugghe et al. 
2013; Sabaté 2003). Non-adherence may lead to subop-
timal clinical outcomes and increased healthcare costs 
(Sabaté 2003).
Adherence rates of patients using oral anti-cancer 
agents have been shown to range from less than 20 to 
100 % (Partridge et al. 2002; Ruddy et al. 2009). Under-
standing of patients’ actual use of medication is essen-
tial for creating treatment conditions that will provide 
optimal clinical benefit. Patient-reported outcomes 
therefore should be taken into consideration in the treat-
ment decision-making process as they better reflect daily 
health status than adverse event assessments by clini-
cians (Basch et al. 2009; Basch 2010). At present, lit-
tle is known about the use of erlotinib in daily practice 
from the patients’ perspective. This study in patients with 
advanced or metastatic NSCLC was designed to assess 
adherence to erlotinib treatment and evaluate experiences 
of patients as well as the relationship between medication 
adherence, erlotinib exposure and symptoms (Timmers 
et al. 2011).
Patients and methods
Study design
This prospective observational cohort study (Timmers 
et al. 2011) was conducted between October 2009 and 
July 2011 in 12 Dutch hospitals. Patients with advanced 
NSCLC scheduled for treatment with erlotinib regardless 
their EGFR mutation status were eligible for participa-
tion. Exclusion criteria were: age younger than 18 years 
or inability to fill out a Dutch questionnaire. Patients start-
ing erlotinib were followed for a maximum of 4 months. 
Adherence to erlotinib was measured with a medication 
event monitoring system (MEMS). Blood samples were 
collected after 1, 2 and 4 months. Patients filled out ques-
tionnaires before the start of erlotinib and at monthly 
intervals on treatment. The study was approved by the 
Medical Ethics review board of VU University Medical 
Center (VUMC, Amsterdam, The Netherlands), as well 
as the Medical Ethics review board of each participating 
centre. Written informed consent was obtained from all 
patients.
Data collection
Medication adherence
Adherence was measured using MEMS (SIMpill®, Evalan, 
Amsterdam, The Netherlands). This pill box contains an 
electronic processor that records all time-points the box is 
opened. MEMS data were used for observational purposes 
only. Only MEMS data from patients who used erlotinib 
>7 days were included for this analysis. Adherence was 
expressed as the proportion of days covered (PDC) and 
was calculated by the number of days on which the box 
was opened divided by the total number of days of treat-
ment (for a maximum of 4 months) × 100 %. To calculate 
the proportion of days with multiple openings (PDMO), the 
number of days on which the box was opened at least twice 
was divided by the total number of days of treatment (for a 
maximum of 4 months) × 100 %. Multiple openings on the 
first and last day of use were not considered for calculation 
of PDMO.
Erlotinib AUC
A steady-state blood sample was collected at regular visits 
after 1, 2 and 4 months of treatment in those patients taking 
erlotinib 150 mg/day. The time of blood withdrawal and the 
time of the last ingestion of erlotinib before blood sampling 
were registered. Samples were centrifuged, and the plasma 
was stored at −20 °C until analysis.
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Plasma concentrations of erlotinib were analysed by 
a validated liquid chromatography MS/MS method. The 
lower limit of quantification (LLOQ) was set at 7 ng/
ml. For post hoc estimation of the area under the curve 
(0–24 h) at steady state (AUCss), the data were analysed 
with the NONMEM program (version VII, level 2 ICON), 
using a one-compartment first-order absorption and elimi-
nation model adapted from the model described by Lu 
et al. (2006). The bioavailability F was set at 1. The typical 
population values for the parameters: absorption constant, 
Ka (0.89 h−1), clearance (4.29 L/h) and volume of distri-
bution V (210 L) were set according to the publication of 
Lu et al. Covariates (total bilirubin, α1-acid glycoprotein, 
smoking) in the model were tested with backward elimina-
tion for our population. Selection of the covariates of the 
model was based on the likelihood ratio test. The objective 
function value (OFV) is proportional to −2 times the log 
likelihood of the data, given the model; therefore, the dif-
ference between two hierarchic models in OFV (ΔOFV) is 
approximately χ2-distributed. A ΔOFV between the com-
peting models of 3.84 (df = 1), corresponding to a nominal 
p value of <0.05, was required for the more complex model 
to be regarded as significantly better than the less complex 
one. After the model was selected, systemic exposure to 
erlotinib as AUCss was calculated.
Questionnaires
At baseline, patients were asked to fill out questionnaires 
including demographic characteristics, smoking, co-med-
ication (including acid-inhibiting medication), quality of 
life [Short Form-12 Health Survey (SF-12)] (Aaronson 
et al. 1998; Gandek et al. 1998), attitude towards medica-
tion in general and specifically towards erlotinib (Beliefs 
about Medicines Questionnaire [BMQ]) (Horne et al. 
1999), illness perception (Brief Illness Perception Ques-
tionnaire [Brief IPQ]) (Broadbent et al. 2006) and symp-
toms. After each month of treatment, patients filled out 
questionnaires about adherence behaviour (Medication 
Adherence Report Scale [MARS]) (Butler et al. 2004; 
Horne et al. 2001), overuse, erlotinib intake in relation to 
food intake, quality of life, illness perception, patients’ atti-
tude towards medication in general and specifically towards 
erlotinib and symptoms. Intake of erlotinib in relation to 
food intake was scored as incorrect when patients reported 
taking erlotinib <60 min before or <120 min after food 
intake. The questions on symptoms were distracted from 
the literature on erlotinib toxicities occurring in >10 % of 
patients, and answers were scored on a 5 point Likert scale 
(not at all, a little bit, rather, a lot, very much). The scores 
at baseline and the scores during use were considered as, 
respectively, baseline health problems and patient-reported 
symptoms. Patient-reported symptoms scored as ‘a lot’ or 
‘very much’ were considered as ‘severe’. Patients taken 
off treatment before the end of the four-month follow-up 
period were asked to fill out questions about reasons for 
discontinuation.
Patients’ medical file
Information on disease characteristics and dose adjust-
ment or interruption by the physician was derived from the 
patients’ medical file.
Statistics
Baseline descriptive data were analysed as frequencies 
(percentages) for categorical variables and as the mean 
(±standard deviation) for continuous data. Adherence over 
time was summarized by mean PDC and mean PDMO per 
time-period. Associations between baseline characteristics 
and incorrect use of erlotinib separately from food were 
assessed in univariate logistic regression analyses in which 
incorrect use was taken as the dependent variable. Associa-
tions between repeatedly measured variables and incorrect 
intake of erlotinib over time were tested using generalized 
estimating equation analyses (GEE). The nonparamet-
ric Mann–Whitney test was used to compare the AUC of 
patients with and without symptoms and patients using 
and not using acid-inhibiting medication (i.e. proton-pump 
inhibitors or histamine H2-receptor antagonists) at one 
month. For the comparison between patients with or with-
out symptoms, two separate analyses were performed using 
different cut-off points: ‘not at all’ versus ‘any symptom’, 
and ‘not at all’ or ‘a little bit’ (no and mild) versus ‘rather’, 
‘a lot’, or ‘very much’ (moderate and severe). The Fisher 
exact test was used to compare patient-reported symptoms 
from the present study with adverse events as reported in 
the BR.21 clinical trial using the Common Terminology 
Criteria for Adverse Events (CTCAE) system (vs. 2) (Shep-
herd et al. 2005). For all analyses, a two-tailed significance 
level of 0.05 was used. p values below this level were con-
sidered statistically significant. The statistical analyses 
were performed with SPSS 20.0 for Windows (IBM Corp, 
Armonk, NY, USA).
Results
Baseline characteristics
A total of 62 patients (median age 63.5 years; 53 % male) 
were included, of whom 15 were still on treatment after 
4 months. With the exception of 2 patients, all patients 
started with a once daily dose of 150 mg. Thirteen (22 %) 
dropped out before the measurement at 1 month and 33 
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(53 %) before 2 months. Table 1 provides information 
on the number of patients for which data are available at 
specific time-points. The median duration of treatment of 
the 62 patients was 51.5 days, with a range from 2 days 
to the maximum of the observation period of 120 days. 
Baseline characteristics of the patients are shown in 
Table 2.
Medication adherence
Most patients (55/62, 89 %) used MEMS during the obser-
vation period. Two patients refused to use MEMS, three 
patients used erlotinib <7 days and the MEMS data of 
another 2 patients were not evaluable due to technical prob-
lems. The mean PDC during the observation period was 
96.8 ± 4.0 %, with a range from 85 to 100 % (Table 3). 
Over one-third of patients (19/55) covered <95 % of days. 
Thirty-four patients (62 %) had at least one day with mul-
tiple openings. The mean PDMO of these patients during 
the studied period was 5.6 ± 4.8 %, with a range from 1 
to 21 %. The mean adherence measured with MARS (scale 
5–25) was 24.9 ± 0.4 after 1 month and remained above 
24 on the other time-points. The MARS statements showed 
3 patients (5 %) rarely forgetting to take their erlotinib, 1 
patient (2 %) rarely adjusting the dose and 1 patient (2 %) 
temporarily stopping. 1 patient (2 %) reported to rarely use 
more than prescribed.
Quality of life and patients’ beliefs and attitude
The mean score at baseline of the SF-12 physical compo-
nent was 32.5 ± 9.3, and the SF-12 mental component was 
47.7 ± 8.2. The BMQ subscales were 10.8 ± 2.6 (over-
use), 10.3 ± 2.3 (harm), 19.1 ± 3.2 (necessity), 15.3 ± 4.0 
(concerns) and 4.0 ± 4.5 (differential). The classifica-
tion into 4 attitudinal groups based on their responses to 
the BMQ at baseline was: 40.0 % accepting (high neces-
sity, low concerns), 55.0 % ambivalent (high necessity, 
high concerns), 3.3 % indifferent (low necessity, low con-
cerns) and 1.7 % sceptical (low necessity, high concerns). 
The mean scores of Brief IPQ at baseline were 8.0 ± 1.9 
(consequences), 8.5 ± 2.5 (time line), 4.0 ± 2.8 (personal 
control), 6.4 ± 2.3 (treatment control), 7.9 ± 2.3 (iden-
tity), 6.0 ± 2.8 (concern), 5.7 ± 3.3 (understanding) and 
5.4 ± 2.9 (emotional response).
Symptoms
Patient-reported symptoms are listed in Table 4. The most 
reported symptoms at baseline were fatigue (89 %), emo-
tional symptoms (anger, fear, depression and/or mood 
swings) (74 %), dyspnoea (71 %) and cough (70 %). After 
1 month of treatment, fatigue (91 %), rash (86 %), cough 
(77 %), anorexia (74 %), emotional symptoms (67 %), 
dyspnoea (66 %) and diarrhoea (66 %) were the symp-
toms most commonly reported. Fatigue was the symptom 
most commonly occurring at baseline (89 %) and during 
treatment (91, 83, 88 and 85 % at, respectively, 1, 2, 3 and 
4 months). Severe symptoms most commonly reported after 
1 month of treatment were rash (39 %), fatigue (32 %), 
sleeping problems (29 %) and anorexia (21 %).
Table 5 shows the change in patient-reported symptoms 
over time for patients with at least 2 months of follow-up.
Patient-reported symptoms mentioned after 1 month 
(n = 49) were compared with adverse events observed in 
the pivotal phase III BR.21 study (Shepherd et al. 2005) 
Table 1  Number of patients for which data are available at time-
point
MEMS, medication event monitoring system; T0, baseline; T1, T2, 
T3 and T4 represent time-points 1, 2, 3 and 4 months
T0 T1 T2 T3 T4
Patients on treatment 62 49 29 17 15
Adherence MEMS 55 45 27 16 14
Blood sample x 42 28 x 13
Questionnaire 62 47 27 17 14
MEMS + blood sample x 39 26 x 12
MEMS + questionnaire 55 44 25 16 13
Blood sample + questionnaire x 41 26 x 12
MEMS + blood sample + questionnaire x 39 24 x 11
Table 2  Baseline characteristics
SD standard deviation
a Number of patients with data available
b Maximum observation period was 120 days
na %
Age median (years) 62 63.5
 Range 46–80
Male 62 53.2
Low education 60 40.0
Living alone 62 14.5
Paid work 58 17.2
Smoking 62 19.4
Co-morbidity 61 65.6
Co-medication 62 82.3
Number of drugs 51
 Mean ± SD 5.0 ± 2.8
 Range 1–13
Initial erlotinib dose 150 mg 60 98.3
Duration of use (days) 62
 Mean ± SD 58.3 ± 39.4
 Range 2–120b
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(Table 6). Though not significantly different from the tox-
icities reported in BR.21 (p > 0.05), the occurrence of 
most patient-reported symptoms (fatigue, rash, anorexia, 
diarrhoea, nausea/vomiting and stomatitis) was higher 
than the adverse events scored by clinicians in the BR.21 
study. Ocular symptoms were reported more frequently 
by patients in the present study and infection less often as 
compared to BR.21 (p < 0.05).
Adherence and use in daily practice
Most patients (>70 %) reported to use any reminder 
method to support the erlotinib intake. None of the patients 
reported the intake of grapefruit or grapefruit juice dur-
ing treatment with erlotinib. No relationship was found 
between adherence (assessed with MEMS) and the use of 
a reminder method. After 1 month, 21 % of patients did not 
Table 3  Adherence to erlotinib as measured with MEMS
PDC proportion of days covered, PDMO proportion of days with multiple openings, SD standard deviation, MEMS medication event monitoring 
system
n Mean ± SD Median Range
Duration of use (days) 55 60.2 ± 38.8 52.0 6.0–120.0
PDC 55 96.8 ± 4.0 98.0 85.0–100.0
 PDC (period 0–28 days) 55 97.5 ± 5.0 100.0 71.4–100.0
 PDC (period 29–56 days) 39 96.5 ± 6.4 100.0 71.4–100.0
 PDC (period 57–max 120 days) 25 95.2 ± 6.7 100.0 75.0–100.0
PDMO 34 5.6 ± 4.8 4.1 1.0–21.2
%
100 % PDC 55 43.6
≥95 % PDC 55 65.5
≥90 % PDC 55 92.7
Table 4  Patient-reported symptoms
Missing data excluded from frequency analyses
T0, at baseline; T1, at 1 month; T2, at 2 months; T3, at 3 months; T4, at 4 months
a % of patients with symptoms reported as ‘a lot’ or ‘very much’
b % of patients with a (any grade) symptom score higher than the score at baseline
n % any  % severea  % increaseb
T0 T1 T2 T3 T4 T0 T1 T2 T3 T4 T1 T2 T3 T4
62 49 29 17 15 62 49 29 17 15 49 29 17 15
Fatigue 88.5 90.9 82.6 88.2 84.6 26.2 31.8 17.4 17.6 23.1 21.7 52.2 58.8 53.8
Rash 14.8 81.8 87.0 82.4 84.6 3.3 38.6 30.4 29.4 38.5 81.8 81.8 81.3 91.7
Anorexia 54.8 70.5 60.9 52.9 61.5 8.1 20.5 21.7 23.5 15.4 39.1 39.1 35.3 23.1
Diarrhoea 19.4 65.9 65.2 52.9 76.9 1.6 11.4 13.0 17.6 15.4 56.5 52.2 52.9 69.2
Ocular symptoms 26.2 59.1 39.1 35.3 69.2 0 4.5 4.3 0 0 36.4 22.7 18.8 41.7
Nausea/vomiting 23.0 51.2 30.4 23.5 23.1 6.6 14.6 4.3 5.9 0 33.3 28.6 12.5 8.3
Stomatitis 3.3 22.0 14.3 29.4 38.5 0 7.3 4.8 5.9 7.7 16.7 11.1 31.3 41.7
Infection 1.7 11.6 8.7 17.6 41.7 0 2.3 0 5.9 8.3 0.0 4.5 18.8 36.4
Cough 70.0 76.7 77.3 64.7 53.8 5.0 9.3 9.1 0 23.1 20.0 35.0 12.5 33.3
Dyspnoea 71.0 65.9 60.9 64.7 66.7 9.7 18.2 8.7 17.6 25.0 26.1 39.1 41.2 41.7
Sleep problems 47.5 45.5 39.1 53.3 46.2 13.1 28.6 4.3 13.3 15.4 13.6 13.6 26.7 23.1
Emotional symptoms 74.1 67.4 56.5 70.6 69.2 13.6 13.6 4.3 5.9 15.4 33.3 28.6 40.0 36.4
Stomach ache 23.0 37.2 43.5 47.1 30.8 4.9 2.3 0 0 0 19.0 38.1 37.5 25.0
Headache 31.3 20.5 21.7 11.8 30.8 3.3 0 0 0 0 4.5 9.1 6.3 16.7
Pain when breathing 13.1 14.0 17.4 25.0 15.4 0 0 0 0 7.7 0.0 13.6 13.3 8.3
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always correctly take erlotinib without food. Tables 7 and 
8 show the risk factors of not always taking erlotinib under 
fasting conditions. Significant relationships with incor-
rect intake were: older age (OR 1.10, 95 % CI 1.00–1.21), 
MARS < 25 (OR 4.83, 95 % CI 1.06–21.99), oculair symp-
toms (OR 3.13, 95 % CI 1.11–8.82) and stomatitis (OR 
6.59, 95 % CI 1.77–24.60).
AUC
The mean AUCss (μg*h/mL) of erlotinib at 1, 2 and 
4 months of treatment was 37.8 ± 15.7 (n = 42), 
36.8 ± 15.8 (n = 28) and 40.5 ± 20.4 (n = 13), respec-
tively. The relationship between the AUC and patient-
reported symptoms at 1 month is presented in Table 9. 
The mean AUC of erlotinib was significantly higher in 
patients who reported rash (any severity) (p < 0.05). The 
comparison of the AUC of erlotinib in patients report-
ing symptoms at the levels ‘not at all’ or ‘a little bit’ (no 
and mild) with the AUC in those reporting symptoms at 
the levels ‘rather’, ‘a lot’, or ‘very much’ (moderate and 
severe) at 1 month was only significantly different for 
anorexia. Patients reporting moderate or severe anorexia 
had a significantly higher AUC than patients reporting no 
or mild anorexia (44.8 ± 4.7 vs. 33.5 ± 2.7 μg*h/mL, 
p < 0.05). A substantial number of patients (39 %) used 
Table 5  Longitudinal 
description of patient-reported 
symptoms
T0, at baseline; T1, at 1 month; 
T2, at 2 months
(n = 29) T0 T1 T2
% any % severe % any % severe % any % severe
Fatigue 82.6 25.0 87.0 20.7 82.6 17.4
Rash 9.1 0 86.4 24.7 86.4 30.4
Anorexia 56.5 3.4 73.9 13.8 60.9 21.7
Diarrhoea 17.4 0 69.6 10.3 65.2 13.0
Ocular symptoms 22.7 0 54.5 3.4 36.4 4.3
Nausea/vomiting 19.0 7.1 38.1 10.7 28.6 4.3
Stomatitis 0.0 0 16.7 3.7 11.1 4.8
Infection 0.0 0 0.0 0 4.5 0
Cough 70.0 7.4 75.0 7.1 75.0 9.1
Dyspnoea 65.2 6.9 52.2 10.3 60.9 8.7
Sleep problems 50.0 10.7 40.9 10.3 40.9 4.3
Emotional symptoms 76.2 7.7 57.1 10.3 57.1 4.3
Stomach ache 4.8 0 23.8 3.6 42.9 0
Headache 31.8 0 22.7 3.4 18.2 0
Pain when breathing 18.2 0 4.5 0 13.6 0
Table 6  Patient-reported symptoms versus clinical trial adverse 
events**
PRO patient-reported outcomes
* Significant; T1, at 1 month; ** symptoms scored by patients in 
this study and adverse events scored by clinicians in the BR.21 trial 
(CTCAE vs. 2) independent of severity
a BR.21 trial (Shepherd et al. 2005)
T1 PRO Clinical triala p value
n % n %
Fatigue 44 90.9 485 79 0.075
Rash 44 81.8 485 76 0.461
Anorexia 44 70.5 485 69 0.057
Diarrhoea 44 65.9 485 55 0.205
Ocular symptoms 44 59.1 485 28 <0.001*
Nausea/vomiting 41 51.2 485 40 0.186
Stomatitis 41 22.0 485 19 0.679
Infection 43 11.6 485 34 <0.001*
Table 7  Relations with incorrect intake of erlotinib under fasting 
conditionsa
Missing data excluded from analyses
OR odds ratio, CI confidence interval
* Significant
a Analyses of baseline characteristics using logistic regression
N = 41 OR 95 % CI p value
Male 1.20 0.30–4.80 0.797
Age 1.10 1.00–1.21 0.041*
Low education 3.00 0.69–13.12 0.144
Living alone 0.50 0.05–4.83 0.549
No paid work 2.86 0.31–26.74 0.356
No smoking 1.54 0.15–15.49 0.715
No Co-morbidity 2.80 0.68–11.59 0.155
Number of co-medication 0.96 0.75–1.22 0.717
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an acid-inhibiting drug (a proton-pump inhibitor or a his-
tamine H2-receptor antagonist). The AUC of erlotinib of 
this patient group did not differ between those who did 
use and those who did not use acid-inhibiting medication 
(AUC, respectively, 34.5 ± 13.4 vs. 41.4 ± 19.1 μg*h/
mL, p = 0.283).
Discontinuation
Twenty-six patients filled out the questions on reasons for 
discontinuation. Thirty-one per cent of them reported side 
effects as a reason to stop erlotinib treatment, whereas 
69 % stopped treatment because of lack of clinical efficacy. 
Most patients (88 %) discontinued on the initiative of their 
physician.
Discussion
NSCLC patients prescribed erlotinib were highly compli-
ant. The mean adherence was 96.8 % ± 4.0.
The high adherence rate might be explained by the life-
threatening nature of the disease and the short treatment 
period. Sub-optimal adherence to oral anticancer medica-
tion is more often an issue in long-term treatments, such 
as adjuvant endocrine treatment prescribed after primary 
breast cancer or TKI treatment of chronic myeloid leu-
kaemia (Ruddy et al. 2009; Marin et al. 2010; Partridge 
et al. 2010). The median duration of treatment with erlo-
tinib in the present study was 52 days, mainly driven by 
lack of clinical efficacy. Treatment duration was grossly 
comparable with that in unselected patients on erlotinib in 
the BR.21 trial in whom a progression-free survival was 
measured of 2.2 months (Shepherd et al. 2005). In our 
study, erlotinib patients were included without knowledge 
of the EGFR mutation status in tumour tissue. As erlotinib 
is now increasingly used in pre-selected patients, the dura-
tion of use may increase. This might negatively influence 
adherence.
In the present study, 93 % of the patients had a PDC 
of at least 90 %. However, over one-third of all patients 
used erlotinib in <95 % of the prescribed days. Adherence 
rates of 80–95 % are generally considered as a minimum 
to obtain an optimal medication efficacy (Osterberg and 
Blaschke 2005; Ruddy et al. 2009). Adherence <95 %, 
measured with the self-report Basel Assessment of Adher-
ence Scale (BAAS), has previously been shown related to 
poorer rates of response to erlotinib (Gebbia et al. 2013). 
The considerable number of patients (34.5 %) who had 
a PDC below 95 % confirms that medication adherence 
might be a relevant issue for this drug.
A minority of patients (21 %) reported occasionally 
not to follow the recommendations regarding the intake 
of erlotinib under fasting conditions. Erlotinib should be 
swallowed at least 1 h before or 2 h after intake of a meal 
(EMA 2014). Intake under fasting conditions is necessary 
because food can substantially increase erlotinib plasma 
levels (Ling et al. 2008), which may cause undesirable 
adverse events. The presence of stomatitis was significantly 
related with sub-optimal intake relative to time-points of a 
Table 8  Relations with incorrect intake of erlotinib under fasting 
conditionsa
No OR could be estimated for fatigue and emotional symptoms. 
Missing data excluded from analyses
OR odds ratio, CI confidence interval, SF-12 short form-12 health 
survey, BMQ beliefs about medicines questionnaire, Brief IPQ illness 
perception questionnaire, MARS medication adherence report scale
* Significant
a Analyses using generalized estimated equations (GEE)
N = 40 OR 95 % CI p value
SF-12
 Physical component 1.00 0.99–1.01 0.959
 Mental component 1.02 1.00–1.04 0.079
BMQ
 General overuse 0.97 0.92–1.02 0.279
 General harm 0.97 0.92–1.03 0.306
 Specific necessity 1.01 0.97–1.04 0.774
 Specific concerns 0.99 0.97–1.02 0.593
 Necessity-concerns differential 1.00 0.99–1.02 0.564
Brief IPQ
 Consequences 1.01 0.97–1.04 0.691
 Time line 1.01 0.96–1.07 0.588
 Personal control 0.97 0.94–1.00 0.085
 Treatment control 1.03 0.96–1.11 0.374
 Identity 1.02 0.97–1.06 0.417
 Concern 0.97 0.94–1.01 0.124
 Understanding 0.98 0.95–1.02 0.313
 Emotional response 0.99 0.96–1.02 0.449
MARS < 25 4.83 1.06–21.99 0.042*
No reminder method 2.79 0.52–14.82 0.229
Patient-reported symptom (any severity)
 Rash 2.52 0.44–14.21 0.295
 Anorexia 0.36 0.11–1.20 0.097
 Diarrhoea 8.16 0.43–154.09 0.161
 Ocular symptoms 3.13 1.11–8.82 0.031*
 Nausea/vomiting 0.62 0.13–3.02 0.554
 Stomatitis 6.59 1.77–24.60 0.005*
 Infection 1.18 0.12–12.02 0.891
 Cough 0.32 0.08–1.25 0.102
 Dyspnoea 5.69 0.83–38.87 0.076
 Sleep problems 0.59 0.15–2.32 0.454
 Stomach ache 1.69 0.44–6.50 0.445
 Headache 0.95 0.18–4.99 0.956
 Pain when breathing 0.49 0.08–3.04 0.443
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meal (OR 6.59, p = 0.005). Stomatitis may influence the 
eating habits and result in an irregular or complex schedule 
of separation of medication from food. Sub-optimal adher-
ence (MARS < 25) was also significantly related with sub-
optimal intake relative to time-points of a meal (OR 4.83, 
p = 0.042). This can be expected, since incorrect intake 
relative to time-points of a meal, is an aspect of sub-opti-
mal adherence. Older age (OR 1.10, p = 0.041) and ocular 
symptoms (OR 3.13, p = 0.031) might also have contrib-
uted to non-adherence. Particularly in case of stomatitis, 
food intake during the use of erlotinib should be carefully 
addressed by healthcare professionals, on the one hand, to 
support patients in correctly taking erlotinib in the absence 
of food and, on the other hand, to avoid anorexia.
As expected, NSCLC patients experienced a variety of 
symptoms. At baseline, their physical quality of life score 
was considerably lower (32.5 ± 9.3) than reported for 
the general population in the Netherlands (47.9 ± 0.6 for 
45- to 64-year-olds; 45.2 ± 10.5 for 65- to 74-year-olds). 
This also holds for the mean mental score (47.7 ± 8.2 vs. 
51.4 ± 9.6 for 45- to 64-year-olds and 52.9 ± 8.6 for 65- 
to 74-year-olds (Gandek et al. 1998). The distribution of 
patients across the four BMQ-belief groups in our popula-
tion shows the majority of patients being ambivalent (high 
necessity, high concerns). This is different from patients 
with the diseases asthma, cardiac disease, depression or 
diabetes, where most patients had an accepting (high neces-
sity, low concerns) attitude towards medication (Tibaldi 
et al. 2009). The severity of the disease and expected symp-
toms experienced during treatment might play an important 
role in the high concerns about the medication.
An important issue to address is the role of patients in 
the assessment of health problems and symptoms to obtain 
insight into side effects they experience from drug medica-
tion (Basch 2010). Advanced NSCLC patients using erlo-
tinib report many health problems, which may not only be 
caused by their medication but also result from their dis-
ease and its progress. In oncology, the collection of data 
on side effects is clinician based and highly regulated by 
the CTCAE system (Trotti et al. 2007). A comparison of 
patient-reported symptoms which occurred in the present 
real-world study with adverse event data from the clini-
cal trial on erlotinib in NSCLC patients confirms the use-
fulness of patient-reported outcomes (Basch et al. 2009, 
2012; Basch 2010). Although most symptoms did not sig-
nificantly differ from those scored by clinicians, especially 
symptoms in the less specific domain were reported more 
often by patients. Patients’ experiences should always be 
taken into account, since one-third of the patients reported 
symptoms as one of the reasons to discontinue treatment. 
This finding is in line with the results of a previous study in 
patients using oral anticancer agents (Timmers et al. 2014). 
Since 88 % of patients discontinued on the initiative of 
their physician, symptoms reported by the patient may very 
well have coincided with lack of benefit from erlotinib.
The mean AUC of erlotinib was higher in patients who 
reported rash (any severity), p < 0.05. The relationship 
between erlotinib exposure and skin rash has been dem-
onstrated previously (Lu et al. 2006; Rudin et al. 2008; 
Thomas et al. 2009), though the absence of a link between 
exposure and rash was found as well (Mita et al. 2011). 
Skin rash is a sign used in clinical practice as indicative for 
clinical benefit since patients with a high grade of skin rash 
may experience a longer progression-free and overall sur-
vival (Krawczyk et al. 2013; Perez-Soler et al. 2004; Pet-
relli et al. 2012b; Wacker et al. 2007), though dosing till 
rash to optimize efficacy is controversial (Mita et al. 2011; 
Brahmer et al. 2014).
Nowadays, erlotinib is prescribed preferentially for 
treatment of selected NSCLC patients. The presence of 
activating EGFR gene mutations and high EGFR gene copy 
number are predictors of an improved clinical outcome, 
while the role of KRAS mutations still needs to be eluci-
dated (Zhu et al. 2008; Cadranel et al. 2012). Currently, it 
is advised to assess the EGFR status before starting first-
line treatment with erlotinib (Brugger et al. 2011; Califano 
et al. 2012). The use of erlotinib in second-line treatment 
Table 9  Relationship between AUCss and patient-reported symptoms 
(T1)
Missing data excluded from analyses
AUCss, area under the curve at steady state; T1, at 1 month; SD, 
standard deviation
* Significant
(n = 41) No symptom AUC 
(µg*h/mL)
Symptom AUC  
(µg*h/mL)
p value
Symptom n Mean ± SD n Mean ± SD
Fatigue 4 26.2 ± 3.0 34 39.3 ± 2.8 0.074
Rash 7 27.8 ± 4.7 31 40.2 ± 2.8 0.030*
Anorexia 11 32.4 ± 4.8 27 40.2 ± 3.0 0.082
Diarrhoea 14 35.5 ± 4.4 24 39.4 ± 3.2 0.520
Ocular symp-
toms
18 39.6 ± 4.6 20 36.4 ± 2.6 0.919
Nausea/vomiting16 33.6 ± 2.7 19 42.3 ± 4.4 0.286
Stomatitis 28 36.8 ± 2.6 8 43.3 ± 8.4 0.614
Infection 33 38.3 ± 2.9 4 34.8 ± 6.0 0.944
Cough 7 35.2 ± 3.6 30 39.3 ± 3.1 0.747
Dyspnoea 13 32.7 ± 3.4 25 40.7 ± 3.4 0.188
Sleep problems 20 35.6 ± 2.9 18 40.6 ± 4.4 0.534
Emotional symp-
toms
11 34.3 ± 4.6 26 39.7 ± 3.2 0.256
Stomach ache 23 38.6 ± 3.9 15 36.9 ± 2.9 0.768
Headache 31 37.4 ± 3.0 7 40.3 ± 5.0 0.354
Pain when 
breathing
31 38.8 ± 3.1 6 36.9 ± 2.5 0.888
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of EGFR wild-type NSCLC patients is an ongoing debate 
as erlotinib seems less effective than docetaxel (Garassino 
et al. 2013). With a better understanding of the presence of 
genetic mutations as a prerequisite for response, the need 
to use skin rash as a predictor for clinical outcome has 
become of less importance.
Apart from rash, the mean AUC of erlotinib was also 
higher in patients reporting moderate or severe anorexia. 
For other symptoms, such as mucositis, diarrhoea, ocular 
symptoms and fatigue, frequently reported with the use 
of erlotinib (Table 4), there was no apparent relationship 
with the AUC. The use of acid-inhibiting co-medication 
(i.e. proton-pump inhibitors and/or histamine H2-receptor 
antagonists) resulted in a lower mean AUC in the present 
study, though this effect was not significant. It is recom-
mended not to combine erlotinib with gastric acid-sup-
pressive medication because it can reduce bioavailability 
(EMA 2014). However, a recently performed retrospective 
analysis of the BR.21 trial database to evaluate the clinical 
impact of this interaction showed that acid-inhibiting co-
medication had no significant impact on plasma levels or 
outcome (Hilton et al. 2013).
The present study has some strengths and limitations. It 
provides a unique and complete survey of the use of erlo-
tinib from the patients’ perspective. To our knowledge, 
adherence to erlotinib neither has been studied previously, 
nor have real-life data, erlotinib blood samples, patients’ 
experiences, data retrieved from the patient’s medical file 
and pharmacies, and adherence assessed with MEMS has 
been combined in a single study. Unfortunately, the number 
of included patients is limited. The study was performed 
in an unselected NSCLC patient population, resulting in a 
relatively short observation period.
Conclusion
Medication adherence to erlotinib is an issue in a consid-
erable number of patients with advanced NSCLC. Patients 
report to have many health problems at baseline and, as to 
be expected, new symptoms appear during erlotinib treat-
ment. To support patients’ optimal erlotinib intake, clini-
cians need to take adequate measures to ameliorate symp-
toms and to address medication adherence and correct 
intake without food. Especially older patients and those 
who experience stomatitis may need extra attention to sup-
port a correct erlotinib use in daily practice.
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